AstraZeneca (AZN) Up on Enhertu, Imfinzi Cancer Data at ESMO (Revised)

AstraZeneca's (AZN) Enhertu reduces the risk of disease progression by 72% in HER2-positive metastatic breast cancer. Imfinzi plus chemotherapy triple...

from Entrepreneur https://ift.tt/3ijV9J2
via IFTTT